Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization

Table 2 Predictive factors associated with FDG avidity

		Non-avid patients	PET-avid patients	UVA
		n (%)	n (%)	P value
ECOG-PS1	0	9 (60)	8 (40)	0.58
	1	5 (33)	9 (47)
	≥ 2	1 (7)	2 (11)
Gender	Female	1 (7)	8 (42)	0.0474
	Male	14 (93)	11 (58)
Pathology-differentiation	Well	10 (67)	8 (42)	0.311
	Moderate	1 (7)	5 (26)
	Poor	0 (0)	1 (5)
	Unknown	4 (27)	5 (26)
BCLC stage2	A	3 (20)	1 (5)	0.123
	B	6 (40)	4 (21)
	C+	6 (40)	14 (74)
Tumor burden	≤ 50%	14 (93)	15 (79)	0.3554
	> 50%	1 (7)	4 (21)
Portal vein thrombosis	No	14 (93)	15 (79)	0.24
	Yes	5 (33)	10 (53)
Extrahepatic disease	No	14 (93)	17 (90)	1.004
	Yes	1 (7)	2 (11)
Prior treatment	No	9 (60)	10 (53)	0.67
	Yes	6 (40)	9 (47)
Child-Pugh-class	A	14 (93)	17 (90)	1.004
	B	1 (7)	2 (11)
Viral hepatitis	No	8 (53)	14 (74)	0.22
	Yes	7 (47)	5 (26)
Cirrhosis	No	14 (93)	16 (84)	0.41
	Yes	10 (67)	10 (53)
		Median (Range)	Median (Range)
Age		59 (46-84)	71 (57-84)	0.10
PET SUV3		2(2-2)	6(3-20)	-
Initial AFP		12 (1-478)	16 (2-186000)	0.23
Volume treated (mL)		1260 (400-2044)	1091 (191-2340)	0.39
Dose delivered (Gy)		125.9 (111.1-478.6)	128.5 (110.5-467.5)	0.66

¹Eastern Cooperative Oncology Group Performance Status;

²Barcelona Clinic Liver Cancer Staging classification;

³Standardized uptake value;

⁴Fisher’s exact test used. AFP: Alpha feto protein.